Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company / PDMR Shareholding

4 Jan 2017 16:36

RNS Number : 3690T
Proteome Sciences PLC
04 January 2017
 

Proteome Sciences plc

(the "Company")

Holdings in Company and PDMR Shareholding

 

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund ("Vulpes"), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each ("Ordinary Shares") at 5.5 pence per Ordinary Share (the "Transaction"). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,943,715 Ordinary Shares, representing approximately 18.33% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Vulpes Life Sciences Fund

2.

Reason for the Notification

a)

Position/status

Martin Diggle, non-executive director of the Company is a director and partner of Vulpes Life Sciences Fund

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Proteome Sciences plc

b)

LEI

n/a

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB0003104196

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

04 January 2017

Price(s)

Volume(s)

5.5p

105,590

d)

Aggregated information:

· Aggregated volume

· Price

 

105,590 Ordinary Shares of 1 pence each purchased at an average price of 5.5 pence per Ordinary Share

e)

Date of the transaction

04 January 2017

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBLGDBSXGBGRS
Date   Source Headline
3rd Feb 20144:44 pmRNSHolding(s) in Company
27th Dec 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20137:00 amRNSTrading Update
20th Nov 20137:00 amRNSPatient Stratification Biomarkers for Liver Cancer
6th Nov 20132:51 pmRNSHolding(s) in Company
1st Oct 201310:34 amRNSBlocklisting Interim Review
30th Sep 20137:00 amRNSHalf Yearly Report
18th Sep 20132:00 pmRNSKey Assay Development at HUPO
2nd Sep 201312:12 pmRNSHolding(s) in Company
6th Aug 201312:36 pmRNSIssue of Equity
18th Jul 20137:00 amRNSNew Data Shows CK1d Blocks Tau in AD Model
28th Jun 20131:00 pmRNSAGM Statement
28th Jun 20137:00 amRNSPatent Statement
26th Jun 20139:27 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSMajor technology contract
5th Jun 20134:08 pmRNSAnnual Financial Report
30th May 20137:01 amRNSPreliminary Results
19th Apr 20137:00 amRNSTrading Update
2nd Apr 20137:00 amRNSBlock admission return
18th Mar 20137:00 amRNSDevelopments in Alzheimer's Disease
22nd Jan 20137:00 amRNSTrading Statement
31st Dec 20127:00 amRNSCK1D Update
3rd Dec 201211:06 amRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
18th Sep 20124:04 pmRNSBlock Admission Return
18th Sep 20124:01 pmRNSBlock Admission Return
18th Sep 20127:00 amRNSFurther re. University of Geneva Study
20th Aug 20127:00 amRNSRe Agreement
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares
9th Aug 20117:00 amRNSProteome Sciences as Preferred Supplier
26th Jul 20117:00 amRNSAppointment of VP Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.